21 September 2020
The US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) has concluded that all technical sections for the STELFONTA (tigilanol tiglate) application for marketing authorisation are complete. The final stage of administrative review has commenced, with formal registration as a veterinary pharmaceutical expected mid-November 2020 pending approval.
- Forums
- ASX - By Stock
- Qbiotics
Qbiotics, page-124
-
- There are more pages in this discussion • 1,118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online